Pharvaris (NASDAQ:PHVS) Trading Up 6.7% - Still a Buy?

Pharvaris (NASDAQ:PHVS - Get Free Report) was up 6.7% during mid-day trading on Thursday . The stock traded as high as $16.34 and last traded at $16.50. Approximately 26,165 shares changed hands during mid-day trading, a decline of 64% from the average daily volume of 72,652 shares. The stock had previously closed at $15.46.

Analyst Ratings Changes

Several research firms have recently weighed in on PHVS. JMP Securities boosted their price objective on shares of Pharvaris from $46.00 to $55.00 and gave the company a "market outperform" rating in a report on Friday, January 31st. Cantor Fitzgerald decreased their price objective on shares of Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a report on Wednesday, May 14th.

Pharvaris Stock Down 1.1%

The firm has a market capitalization of $864.35 million, a PE ratio of -5.90 and a beta of -2.85. The stock's fifty day simple moving average is $15.45 and its 200 day simple moving average is $17.20.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.89) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.09). On average, analysts predict that Pharvaris will post -2.71 EPS for the current year.

Institutional Trading of Pharvaris

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PHVS. Cubist Systematic Strategies LLC bought a new position in shares of Pharvaris in the fourth quarter worth approximately $64,000. JPMorgan Chase & Co. boosted its position in shares of Pharvaris by 1,125.3% in the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after purchasing an additional 2,847 shares during the period. Legal & General Group Plc boosted its position in shares of Pharvaris by 11.2% in the fourth quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock worth $189,000 after purchasing an additional 994 shares during the period. KLP Kapitalforvaltning AS bought a new position in shares of Pharvaris in the fourth quarter worth approximately $111,000. Finally, Northern Trust Corp boosted its position in shares of Pharvaris by 483.9% in the fourth quarter. Northern Trust Corp now owns 91,932 shares of the company's stock worth $1,762,000 after purchasing an additional 76,188 shares during the period.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.